Physician
Ray, Vera
Ray, Vera was paid $4.44M by Medicaid between Mar 2019 and Jun 2024, across 142 billing codes. Its largest line is U0002, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc — 19% of everything it billed.
33Billing provider infoRAY, VERA
CHICAGO, IL 60615
CHICAGO, IL 60615
33aNPI1598727919assigned 04/03/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$4.44M
24GClaims596,871
24DCodes billed142
24AFirst – last monthMar 2019 – Jun 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#12 of 398
Median peer was paid$66K
This provider vs. median68×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 114,133 | $741K | |
| 2020 | 137,261 | $949K | |
| 2021 | 131,347 | $1.03M | |
| 2022 | 118,115 | $996K | |
| 2023 | 94,230 | $710K | |
| 2024incomplete | 1,785 | $14K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 19% | 21,626 | 17,787 | $849K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 12% | 18,089 | 13,570 | $548K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 7.0% | 6,851 | 5,966 | $312K |
| 85027 | 4.8% | 76,209 | 44,011 | $213K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 4.8% | 9,672 | 7,053 | $212K |
| 80053 | Comprehensive metabolic panel | 3.6% | 32,612 | 22,205 | $162K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.4% | 38,008 | 21,671 | $151K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 5,372 | 4,025 | $117K |
| 86703 | 1.8% | 8,150 | 6,741 | $78K | |
| 87480 | 1.8% | 6,273 | 4,994 | $78K | |
| 87510 | 1.8% | 6,267 | 4,992 | $78K | |
| 83880 | 1.7% | 8,074 | 5,048 | $75K |
130 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.7% | 9,273 | $73K |
| 84484 | 1.6% | 16,814 | $73K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.6% | 3,262 | $70K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.5% | 3,091 | $66K |
| 82805 | 1.4% | 8,003 | $64K | |
| 86480 | 1.3% | 2,165 | $59K | |
| 83735 | 1.3% | 17,790 | $57K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.3% | 6,501 | $56K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 1,445 | $53K |
| 87040 | 1.1% | 4,340 | $49K | |
| 80074 | <1% | 2,237 | $41K | |
| 85610 | <1% | 20,930 | $39K | |
| 83690 | <1% | 10,823 | $36K | |
| 82948 | <1% | 20,238 | $35K | |
| 83605 | <1% | 6,606 | $33K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,498 | $32K |
| 87340 | <1% | 4,734 | $31K | |
| 81025 | <1% | 14,932 | $28K | |
| 87088 | <1% | 5,174 | $28K | |
| 82550 | <1% | 13,194 | $27K | |
| 81000 | <1% | 21,861 | $26K | |
| 80061 | Lipid panel | <1% | 11,929 | $26K |
| 86592 | <1% | 12,578 | $24K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 730 | $24K |
| 84702 | <1% | 4,596 | $23K | |
| 82607 | <1% | 3,430 | $22K | |
| 87400 | <1% | 2,910 | $22K | |
| 83655 | <1% | 2,460 | $17K | |
| 87660 | <1% | 1,510 | $16K | |
| 84100 | <1% | 11,203 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,765 | $16K |
| 80164 | <1% | 3,581 | $15K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,568 | $15K |
| 86850 | <1% | 5,034 | $14K | |
| 86803 | <1% | 1,547 | $13K | |
| 85730 | <1% | 4,423 | $13K | |
| 86901 | <1% | 5,870 | $13K | |
| 85379 | <1% | 3,417 | $12K | |
| 80076 | <1% | 4,670 | $12K | |
| 88304 | <1% | 555 | $11K | |
| 82553 | <1% | 2,935 | $11K | |
| 87081 | <1% | 3,781 | $11K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 719 | $10K |
| 86762 | <1% | 2,519 | $10K | |
| 88307 | <1% | 502 | $10K | |
| 85384 | <1% | 3,636 | $10K | |
| 84439 | <1% | 2,365 | $10K | |
| 84436 | <1% | 2,955 | $9K | |
| 86900 | <1% | 5,407 | $9K | |
| 82728 | <1% | 2,309 | $9K | |
| 80185 | <1% | 1,218 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 149 | $8K |
| 87430 | <1% | 966 | $8K | |
| 83020 | <1% | 1,770 | $7K | |
| 88300 | <1% | 1,094 | $7K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 44 | $7K |
| 82105 | <1% | 739 | $7K | |
| 82746 | <1% | 1,161 | $6K | |
| 85660 | <1% | 2,818 | $6K | |
| 83540 | <1% | 2,020 | $6K | |
| 80202 | <1% | 874 | $6K | |
| 86140 | <1% | 2,596 | $6K | |
| 85651 | <1% | 2,441 | $5K | |
| 86694 | <1% | 795 | $5K | |
| 86328 | <1% | 368 | $4K | |
| 86336 | <1% | 391 | $4K | |
| 84060 | <1% | 1,281 | $4K | |
| 87070 | <1% | 1,322 | $4K | |
| 82747 | <1% | 549 | $4K | |
| 82803 | <1% | 423 | $4K | |
| 82248 | <1% | 2,460 | $3K | |
| 83550 | <1% | 909 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 337 | $3K |
| 83615 | <1% | 1,568 | $3K | |
| 82677 | <1% | 390 | $3K | |
| 86255 | <1% | 702 | $2K | |
| 87420 | <1% | 289 | $2K | |
| 80069 | <1% | 373 | $2K | |
| 83789 | <1% | 554 | $2K | |
| 82247 | <1% | 1,107 | $2K | |
| 83001 | <1% | 208 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,577 | $2K |
| 82533 | <1% | 285 | $2K | |
| 82950 | <1% | 796 | $2K | |
| 87075 | <1% | 306 | $2K | |
| 84403 | <1% | 125 | $2K | |
| 84550 | <1% | 1,110 | $1K | |
| 84146 | <1% | 211 | $1K | |
| 82010 | <1% | 1,117 | $1K | |
| 86696 | <1% | 92 | $1K | |
| 82150 | <1% | 389 | $1K | |
| 82570 | <1% | 484 | $1K | |
| 86695 | <1% | 95 | $1K | |
| 87653 | <1% | 87 | $1K | |
| 86430 | <1% | 331 | $1K | |
| 84402 | <1% | 93 | $847.08 | |
| 86880 | <1% | 388 | $809.10 | |
| 83002 | <1% | 141 | $770.69 | |
| 84153 | <1% | 118 | $696.14 | |
| 86905 | <1% | 388 | $684.19 | |
| 87536 | <1% | 16 | $651.75 | |
| 83498 | <1% | 94 | $617.56 | |
| 82043 | <1% | 296 | $565.06 | |
| 82626 | <1% | 81 | $538.65 | |
| 82947 | <1% | 283 | $532.02 | |
| 85018 | <1% | 288 | $323.64 | |
| 85014 | <1% | 278 | $322.48 | |
| 84155 | <1% | 357 | $307.96 | |
| 87493 | <1% | 13 | $297.83 | |
| 86706 | <1% | 43 | $273.00 | |
| 85045 | <1% | 212 | $247.60 | |
| 84460 | <1% | 108 | $228.29 | |
| 84450 | <1% | 98 | $216.11 | |
| 82670 | <1% | 28 | $209.99 | |
| 84075 | <1% | 95 | $208.58 | |
| 83970 | <1% | 13 | $191.39 | |
| 86735 | <1% | 29 | $184.15 | |
| 83525 | <1% | 38 | $165.24 | |
| 86765 | <1% | 28 | $114.80 | |
| 84300 | <1% | 43 | $81.57 | |
| 84481 | <1% | 15 | $70.51 | |
| 82565 | <1% | 167 | $68.70 | |
| 80178 | <1% | 19 | $66.27 | |
| 85007 | <1% | 22 | $38.50 | |
| 85032 | <1% | 40 | $34.50 | |
| 82800 | <1% | 83 | $20.97 | |
| 80320 | 0% | 600 | $0.00 | |
| 80329 | 0% | 14 | $0.00 | |
| 84145 | 0% | 377 | $0.00 | |
| 80301 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.